Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

34.36 +0.67 (+1.99%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,023,577
Open 34.12
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 33.69
Today's Range 34.12 - 34.44
52wk Range 27.95 - 41.71
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ignore Crypto: These Stocks Could Make You Rich
Investing in solid, growing businesses is a less risky road to riches than investing in Bitcoin or other cryptocurrencies. 
Via The Motley Fool
Genentech and NVIDIA Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development
From Genentech
Via Business Wire

Performance

YTD
-12.50%
-12.50%
1 Month
+6.28%
+6.28%
3 Month
-6.20%
-6.20%
6 Month
-11.05%
-11.05%
1 Year
-16.03%
-16.03%

More News

Read More
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare
Via InvestorPlace
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
Via Benzinga
Exposures Product Safety
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
Via FinancialNewsMedia
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
Via The Motley Fool
BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake
Via Investor's Business Daily
Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug
Via Benzinga
Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks
Via Benzinga
Exposures Product Safety
Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More
Via Benzinga
Exposures Product Safety
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
Via The Motley Fool
FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
From Genentech
Via Business Wire
It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy
Via The Motley Fool
Why Is Roivant Sciences (ROIV) Stock Up Today?
Via InvestorPlace
Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise
Via FinancialNewsMedia
Exposures Product Safety
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space
Via Investor's Business Daily
Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal
Via Benzinga
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
From Roivant Sciences
Via GlobeNewswire
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
Via The Motley Fool
Drug Giant Roche Skids As Covid Products Decline Weighs On Sales, Guidance
Via Investor's Business Daily
Exposures COVID-19
Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products
Via Benzinga
Exposures COVID-19
Genentech’s Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer
From Genentech
Via Business Wire
What's Going On Cancer Player Monte Rosa Therapeutics Stock Today?
Via Benzinga
FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication
Via Benzinga
Exposures Product Safety
Why Is Alzheimer's Player Prothena Stock Trading Higher Today?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.